31st January 2019
Oncimmune Holdings plc (“Oncimmune” or the “Company”)
Notice of Half Year Results
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, will be announcing its half year results for the six months ended 30 November 2018, on Wednesday 13 February 2019.
Adam Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts, followed by a Q&A session, at 11.00am on the day of the results in The Dome Room, 1 Cornhill, London EC3V 3ND.
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, John Goold
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
+44 (0)20 3709 5700
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT®—Lung and EarlyCDT®—Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT®—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com